Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 641 GBX 0.16% Market Closed
Market Cap: 772.4m GBX

Oxford BioMedica PLC
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Oxford BioMedica PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Oxford BioMedica PLC
LSE:OXB
Revenue
ÂŁ151.2m
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
28%
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Revenue
$28.3m
CAGR 3-Years
23%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Revenue
ÂŁ310.2m
CAGR 3-Years
127%
CAGR 5-Years
65%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Revenue
ÂŁ672.8m
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
5%
Avacta Group PLC
LSE:AVCT
Revenue
-ÂŁ11.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Oxford BioMedica PLC
Glance View

Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.

OXB Intrinsic Value
542.47 GBX
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Oxford BioMedica PLC's Revenue?
Revenue
151.2m GBP

Based on the financial report for Jun 30, 2025, Oxford BioMedica PLC's Revenue amounts to 151.2m GBP.

What is Oxford BioMedica PLC's Revenue growth rate?
Revenue CAGR 10Y
28%

Over the last year, the Revenue growth was 55%. The average annual Revenue growth rates for Oxford BioMedica PLC have been 6% over the past three years , 18% over the past five years , and 28% over the past ten years .

Back to Top